Compare Suven Life Sciences with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES ALEMBIC PHARMA SUVEN LIFE SCIENCES/
ALEMBIC PHARMA
 
P/E (TTM) x -88.0 17.0 - View Chart
P/BV x 1.4 6.8 20.5% View Chart
Dividend Yield % 1.7 0.6 294.5%  

Financials

 SUVEN LIFE SCIENCES   ALEMBIC PHARMA
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
ALEMBIC PHARMA
Mar-19
SUVEN LIFE SCIENCES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs338664 50.9%   
Low Rs169412 41.1%   
Sales per share (Unadj.) Rs52.1208.7 25.0%  
Earnings per share (Unadj.) Rs6.831.0 22.0%  
Cash flow per share (Unadj.) Rs8.637.1 23.1%  
Dividends per share (Unadj.) Rs1.505.50 27.3%  
Dividend yield (eoy) %0.61.0 57.9%  
Book value per share (Unadj.) Rs65.3144.2 45.3%  
Shares outstanding (eoy) m127.28188.52 67.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.6 188.6%   
Avg P/E ratio x37.117.4 213.8%  
P/CF ratio (eoy) x29.614.5 204.0%  
Price / Book Value ratio x3.93.7 104.1%  
Dividend payout %22.017.7 123.8%   
Avg Mkt Cap Rs m32,272101,461 31.8%   
No. of employees `0001.1NA-   
Total wages/salary Rs m6617,467 8.9%   
Avg. sales/employee Rs Th6,132.2NM-  
Avg. wages/employee Rs Th611.1NM-  
Avg. net profit/employee Rs Th803.5NM-  
INCOME DATA
Net Sales Rs m6,63539,347 16.9%  
Other income Rs m24294 258.3%   
Total revenues Rs m6,87739,441 17.4%   
Gross profit Rs m1,6048,736 18.4%  
Depreciation Rs m2211,152 19.2%   
Interest Rs m38184 20.5%   
Profit before tax Rs m1,5877,493 21.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,568 45.8%   
Profit after tax Rs m8695,844 14.9%  
Gross profit margin %24.222.2 108.9%  
Effective tax rate %45.220.9 216.2%   
Net profit margin %13.114.9 88.2%  
BALANCE SHEET DATA
Current assets Rs m6,23219,577 31.8%   
Current liabilities Rs m1,49014,896 10.0%   
Net working cap to sales %71.511.9 600.7%  
Current ratio x4.21.3 318.2%  
Inventory Days Days8690 96.3%  
Debtors Days Days8345 182.1%  
Net fixed assets Rs m4,04327,097 14.9%   
Share capital Rs m127377 33.8%   
"Free" reserves Rs m8,18326,811 30.5%   
Net worth Rs m8,31027,188 30.6%   
Long term debt Rs m184,993 0.4%   
Total assets Rs m10,38947,778 21.7%  
Interest coverage x43.141.7 103.4%   
Debt to equity ratio x00.2 1.2%  
Sales to assets ratio x0.60.8 77.6%   
Return on assets %8.712.6 69.2%  
Return on equity %10.521.5 48.7%  
Return on capital %19.523.6 82.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62219,453 28.9%   
Fx outflow Rs m1,7996,065 29.7%   
Net fx Rs m3,82213,388 28.6%   
CASH FLOW
From Operations Rs m3568,120 4.4%  
From Investments Rs m-279-7,556 3.7%  
From Financial Activity Rs m-225590 -38.1%  
Net Cashflow Rs m-1481,153 -12.9%  

Share Holding

Indian Promoters % 63.4 74.1 85.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.9 -  
FIIs % 0.0 9.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 13.9 262.6%  
Shareholders   37,287 49,328 75.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   PFIZER  GSK PHARMA  FRESENIUS KABI ONCO.  WYETH  ABBOTT INDIA  

Compare SUVEN LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Apr 15, 2021 03:37 PM

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS